Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a phase 1B/2 study.
Matasar, M Herrera, A Kamdar, M Mehta, A Assouline, S Fleury, I Kim, T Kim, W Bosch, F
Matasar, M
Herrera, A
Kamdar, M
Mehta, A
Assouline, S
Fleury, I
Kim, T
Kim, W
Bosch, F
Citations
Altmetric:
Abstract
Affiliation
Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021
Description
Lymphoma Research Team
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma: Updated results of a phase 1B/2 study. 2017, 102:173-173 Haematologica